Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 17 studies | 34% ± 10% | |
peripheral blood | 13 studies | 28% ± 11% | |
brain | 10 studies | 31% ± 11% | |
intestine | 9 studies | 24% ± 11% | |
kidney | 6 studies | 28% ± 5% | |
liver | 5 studies | 27% ± 11% | |
pancreas | 4 studies | 44% ± 20% | |
placenta | 4 studies | 33% ± 7% | |
eye | 4 studies | 25% ± 5% | |
uterus | 4 studies | 33% ± 13% | |
breast | 4 studies | 28% ± 5% | |
lymph node | 3 studies | 24% ± 3% | |
bone marrow | 3 studies | 20% ± 7% | |
prostate | 3 studies | 19% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 14000.53 | 1445 / 1445 | 100% | 220.95 | 183 / 183 |
liver | 100% | 12609.99 | 226 / 226 | 100% | 202.67 | 406 / 406 |
pancreas | 100% | 9010.55 | 328 / 328 | 100% | 215.00 | 178 / 178 |
prostate | 100% | 12333.36 | 245 / 245 | 100% | 220.42 | 502 / 502 |
stomach | 100% | 11304.94 | 359 / 359 | 100% | 218.39 | 286 / 286 |
lung | 100% | 20733.15 | 578 / 578 | 100% | 243.29 | 1154 / 1155 |
thymus | 100% | 16897.70 | 653 / 653 | 100% | 256.70 | 604 / 605 |
breast | 100% | 17370.75 | 459 / 459 | 100% | 248.84 | 1116 / 1118 |
intestine | 100% | 14359.54 | 966 / 966 | 100% | 229.42 | 526 / 527 |
ovary | 100% | 13173.99 | 180 / 180 | 100% | 146.55 | 429 / 430 |
bladder | 100% | 15817.81 | 21 / 21 | 100% | 233.49 | 502 / 504 |
uterus | 100% | 16232.46 | 170 / 170 | 100% | 232.77 | 457 / 459 |
kidney | 100% | 17332.66 | 89 / 89 | 100% | 173.08 | 897 / 901 |
skin | 100% | 24627.43 | 1809 / 1809 | 99% | 240.80 | 469 / 472 |
brain | 99% | 7851.71 | 2604 / 2642 | 100% | 173.94 | 705 / 705 |
adrenal gland | 100% | 12381.52 | 258 / 258 | 94% | 144.16 | 217 / 230 |
adipose | 100% | 17855.78 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 22781.79 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 168.70 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 148.09 | 29 / 29 |
spleen | 100% | 13640.85 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 179.69 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 77.52 | 1 / 1 |
heart | 99% | 8549.76 | 850 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 9237.47 | 910 / 929 | 0% | 0 | 0 / 0 |
muscle | 95% | 5341.80 | 762 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0140507 | Biological process | granzyme-mediated programmed cell death signaling pathway |
GO_0045954 | Biological process | positive regulation of natural killer cell mediated cytotoxicity |
GO_0043323 | Biological process | positive regulation of natural killer cell degranulation |
GO_0007042 | Biological process | lysosomal lumen acidification |
GO_0046718 | Biological process | symbiont entry into host cell |
GO_0050821 | Biological process | protein stabilization |
GO_0090160 | Biological process | Golgi to lysosome transport |
GO_1902513 | Biological process | regulation of organelle transport along microtubule |
GO_0072594 | Biological process | establishment of protein localization to organelle |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0031902 | Cellular component | late endosome membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0016020 | Cellular component | membrane |
GO_0044754 | Cellular component | autolysosome |
GO_0005764 | Cellular component | lysosome |
GO_0000421 | Cellular component | autophagosome membrane |
GO_0035577 | Cellular component | azurophil granule membrane |
GO_0042383 | Cellular component | sarcolemma |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005829 | Cellular component | cytosol |
GO_0008021 | Cellular component | synaptic vesicle |
GO_0061474 | Cellular component | phagolysosome membrane |
GO_0005770 | Cellular component | late endosome |
GO_0005771 | Cellular component | multivesicular body |
GO_0005737 | Cellular component | cytoplasm |
GO_0101003 | Cellular component | ficolin-1-rich granule membrane |
GO_0010008 | Cellular component | endosome membrane |
GO_0101004 | Cellular component | cytolytic granule membrane |
GO_0042470 | Cellular component | melanosome |
GO_0005765 | Cellular component | lysosomal membrane |
GO_0019899 | Molecular function | enzyme binding |
GO_0019904 | Molecular function | protein domain specific binding |
GO_0008200 | Molecular function | ion channel inhibitor activity |
GO_0001618 | Molecular function | virus receptor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | LAMP1 |
Protein name | Lysosome-associated membrane glycoprotein 1 (LAMP-1) (Lysosome-associated membrane protein 1) (CD107 antigen-like family member A) (CD antigen CD107a) |
Synonyms | |
Description | FUNCTION: Lysosomal membrane glycoprotein which plays an important role in lysosome biogenesis, lysosomal pH regulation, autophagy and cholesterol homeostasis . Acts as an important regulator of lysosomal lumen pH regulation by acting as a direct inhibitor of the proton channel TMEM175, facilitating lysosomal acidification for optimal hydrolase activity . Also plays an important role in NK-cells cytotoxicity . Mechanistically, participates in cytotoxic granule movement to the cell surface and perforin trafficking to the lytic granule . In addition, protects NK-cells from degranulation-associated damage induced by their own cytotoxic granule content . Presents carbohydrate ligands to selectins . .; FUNCTION: (Microbial infection) Acts as a receptor for Lassa virus glycoprotein . Promotes also fusion of the virus with host membrane in less acidic endosomes . .; FUNCTION: (Microbial infection) Supports the FURIN-mediated cleavage of mumps virus fusion protein F by interacting with both FURIN and the unprocessed form but not the processed form of the viral protein F. . |
Accessions | P11279 ENST00000332556.5 [P11279-1] |